|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 374.15 USD | +3.55% |
|
+6.05% | +14.31% |
| Jul. 02 | Amgen Wins Preliminary Injunction to Block Colorado From Imposing Price Cap on Arthritis Drug | MT |
| Jul. 02 | Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial | DJ |
| Market Cap | 202B 177B 162B 151B 287B 19,227B 291B 1,948B 757B 9,451B 758B 742B 32,567B | P/E 2026 * |
24.4x | P/E 2027 * | 22.5x |
|---|---|---|---|---|---|
| Enterprise Value | 244B 213B 196B 182B 346B 23,198B 351B 2,350B 913B 11,403B 915B 895B 39,293B | EV / Sales 2026 * |
6.45x | EV / Sales 2027 * | 6.15x |
| Free-Float |
99.78% | Yield 2026 * |
2.7% | Yield 2027 * | 2.85% |
Last Transcript: Amgen Inc.
| 1 day | +3.55% | ||
| 1 week | +6.05% | ||
| Current month | +3.32% | ||
| 1 month | +13.98% | ||
| 3 months | +7.53% | ||
| 6 months | +14.20% | ||
| Current year | +14.31% |
| 1 week | 356.87 |  | 375.15 |
| 1 month | 334.05 | | 375.15 |
| Current year | 318.21 | | 391.29 |
| 1 year | 269.77 | | 391.29 |
| 3 years | 218.44 | | 391.29 |
| 5 years | 198.64 | | 391.29 |
| 10 years | 133.64 | | 391.29 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CEO | Chief Executive Officer | 63 | 2012-04-30 |
| Director of Finance/CFO | 62 | 2010-05-12 | |
Peter Griffith
DFI | Director of Finance/CFO | 67 | 2019-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CHM | Chairman | 63 | 2012-12-31 |
Tyler Jacks
BRD | Director/Board Member | 65 | 2011-12-31 |
Robert Eckert
BRD | Director/Board Member | 71 | 2011-12-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| May. 18 | Free | Director | 665 | 0.0001% | ||
| May. 18 | Free | Director | 665 | 0.0001% | ||
| May. 18 | Free | Director | 665 | 0.0001% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.55% | +6.05% | +26.04% | +68.52% | 202B | |
| +3.45% | +7.65% | +55.77% | +158.84% | 1,082B | |
| -1.16% | +7.42% | +69.09% | +58.92% | 633B | |
| -0.77% | +7.37% | +36.87% | +93.77% | 461B | |
| -0.35% | +1.85% | +31.30% | +24.86% | 339B | |
| -0.56% | +1.17% | +41.96% | +39.64% | 301B | |
| -0.08% | +1.49% | +32.40% | +44.75% | 292B | |
| -1.54% | +2.58% | -25.52% | -39.75% | 225B | |
| +0.40% | +6.00% | +17.72% | +70.33% | 163B | |
| +1.83% | +2.75% | -3.95% | -33.70% | 139B | |
| Average | +1.52% | +2.09% | +28.17% | +48.62% | 383.83B | |
| Weighted average by Cap. | +1.39% | +1.90% | +40.57% | +77.54% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 37.76B 33.01B 30.34B 28.28B 53.64B 3,595B 54.45B 364B 142B 1,767B 142B 139B 6,090B | 38.71B 33.84B 31.1B 28.99B 54.99B 3,686B 55.82B 373B 145B 1,812B 145B 142B 6,244B |
| Net income | 8.23B 7.2B 6.61B 6.16B 11.69B 784B 11.87B 79.39B 30.86B 385B 30.9B 30.23B 1,328B | 8.86B 7.75B 7.12B 6.64B 12.59B 844B 12.78B 85.5B 33.24B 415B 33.27B 32.56B 1,430B |
| Net Debt | 41.7B 36.46B 33.51B 31.23B 59.24B 3,971B 60.13B 402B 156B 1,952B 157B 153B 6,726B | 36.06B 31.52B 28.97B 27B 51.21B 3,433B 51.99B 348B 135B 1,688B 135B 132B 5,815B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-02 | $374.15 | +3.55% | 2,487,837 |
| 26-07-01 | $361.33 | -0.22% | 2,244,791 |
| 26-06-30 | $362.12 | +0.44% | 2,246,908 |
| 26-06-29 | $360.55 | +0.62% | 2,461,887 |
| 26-06-26 | $358.33 | +1.56% | 3,610,561 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- AMGN Stock
Select your edition
All financial news and data tailored to specific country editions
